Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future

Pharmacology and Therapeutics

Volumn 164, Issue , 2016, Pages 195-203

  Lythgoe, Mark P ^a   Rhodes, Christopher J ^a   Ghataorhe, Pavandeep ^a   Attard, Mark ^a   Wharton, John ^a   Wilkins, Martin R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug development; Imatinib; Pulmonary arterial hypertension; Serotonin; Statins; Vasoactive intestinal polypeptide

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TERGURIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; BIOLOGICAL MARKER; DRUG COMBINATION; LISURIDE; PHENTOLAMINE; PROTEIN TYROSINE KINASE;

CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; NONHUMAN; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES;

ANIMALS; BIOMARKERS; CLINICAL STUDIES AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; LISURIDE; PHENOTYPE; PHENTOLAMINE; PROTEIN-TYROSINE KINASES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84969533979     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.04.012     Document Type: Review

References (114)

1. Abraham, W.T., Adamson, P.B., Bourge, R.C., Aaron, M.F., Costanzo, M.R., Stevenson, L.W., Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet 377:9766 (2011), 658–666, 10.1016/S0140-6736(11)60101-3.
2. Adamson, P.B., Abraham, W.T., Aaron, M., Aranda, J.M., Bourge, R.C., Smith, A., CHAMPION trial rationale and design: The long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail 17:1 (2011), 3–10, 10.1016/j.cardfail.2010.08.002.
3. Arrowsmith, J., Trial watch: Phase III and submission failures: 2007-2010. Nat Rev Drug Discov, 10(2), 2011, 87, 10.1038/nrd3375.
4. Baselga, J., Targeting tyrosine kinases in cancer: The second wave. Science (New York, N.Y.) 312:5777 (2006), 1175–1178, 10.1126/science1125951.
5. Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Frantz, R.P., Foreman, A.J., Coffey, C.S., Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:2 (2010), 164–172, 10.1161/CIRCULATIONAHA10989812.
6. Blanpain, C., Poul, E.L., Parma, J., Knoop, C., Detheux, M., Parmentier, M., Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60:3 (2003), 518–528.
7. Chen, L., Nakano, K., Kimura, S., Matoba, T., Iwata, E., Miyagawa, M., Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 57:2 (2011), 343–350, 10.1161/HYPERTENSIONAHA110157032.
8. Ciccarelli, E., Camanni, F., Diagnosis and drug therapy of prolactinoma. Drugs 51:6 (1996), 954–965.
9. Cogolludo, A., Moreno, L., Lodi, F., Frazziano, G., Cobeño, L., Tamargo, J., Perez-Vizcaino, F., Serotonin inhibits voltage-gated K + currents in pulmonary artery smooth muscle cells: Role of 5-HT2A receptors, caveolin-1, and KV15 channel internalization. Circ Res 98:7 (2006), 931–938, 10.1161/01RES000021685804599e1.
10. Connolly, M.J., Aaronson, P.I., Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulm Pharmacol Ther 24:1 (2011), 1–14, 10.1016/jpupt201009001.
11. Dai, L., Wu, S., Atorvastatin attenuates hypoxic pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36:1 (2011), 58–63, 10.3969/jissn1672-7347201101009.
12. D'Alonzo, G.E., Barst, R.J., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., Detre, K.M., Survival in patients with primary pulmonary hypertension Results from a national prospective registry. Ann Intern Med 115:5 (1991), 343–349.
13. Day, E., Waters, B., Spiegel, K., Alnadaf, T., Manley, P.W., Buchdunger, E., Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599:1–3 (2008), 44–53, 10.1016/jejphar200810014.
14. de Kogel, C.E., Schellens, J.H., Imatinib. Oncologist 12:12 (2007), 1390–1394, 10.1634/theoncologist12-12-1390.
15. Delcroix, M., Kurz, X., Walckiers, D., Demedts, M., Naeije, R., High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 12:2 (1998), 271–276.
16. DeMarco, V.G., Habibi, J., Whaley-Connell, A.T., Schneider, R.I., Sowers, J.R., Andresen, B.T., Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol 297:3 (2009), H1128–H1139, 10.1152/ajpheart000482009.
17. Deng, Z., Morse, J.H., Slager, S.L., Cuervo, N., Moore, K.J., Venetos, G., Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:3 (2000), 737–744, 10.1086/30305.
18. Dumitrascu, R., Kulcke, C., Königshoff, M., Kouri, F., Yang, X., Morrell, N., Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 37:5 (2011), 1104–1118, 10.1183/0903193600126010.
19. Eddahibi, S., Humbert, M., Fadel, E., Raffestin, B., Darmon, M., Capron, F., Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108:8 (2001), 1141–1150, 10.1172/JCI12805.
20. Esch, E.W., Bahinski, A., Huh, D., (2015) Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 14:4 (2015), 248–260, 10.1038/nrd4539.
21. Fröhlich, G.M., Rufibach, K., Enseleit, F., Wolfrum, M., von Babo, M., Frank, M., Statins and the risk of cancer after heart transplantation. Circulation 126:4 (2012), 440–447, 10.1161/CIRCULATIONAHA111081059.
22. Gabler, N.B., French, B., Strom, B.L., Liu, Z., Palevsky, H.I., Taichman, D.B., Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141:1 (2012), 20–26, 10.1378/chest11-0404.
23. Gao, Y.-F.F., Zhu, X.-D.D., Shi, D.-M.M., Jing, Z.-C.C., Li, L., Ma, D., The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. Int J Mol Med 26:4 (2010), 541–547.
24. Ghofrani, H.A.A.-H.H., Al-Hiti, H., Vonk- Noordegraaf, A., Behr, J., Neurohr, C., Jansa, P., Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs placebo in subjects with pulmonary arterial hypertension: Results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med, 185, 2012, A2496.
25. Ghofrani, H.A., Morrell, N.W., Hoeper, M.M., Olschewski, H., Peacock, A.J., Barst, R.J., Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182:9 (2010), 1171–1177, 10.1164/rccm201001-0123OC.
26. Girgis, R.E., Li, D., Zhan, X., Garcia, J., Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285:3 (2003, Sep), H938–H945, 10.1152/ajpheart010972002.
27. Girgis, R.E., Mozammel, S., Champion, H.C., Li, D., Peng, X., Shimoda, L., Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 292:5 (2007), L1105–L1110, 10.1152/ajplung004112006.
28. Guerard, P., Rakotoniaina, Z., Goirand, F., Rochette, L., Dumas, M., Lirussi, F., Bardou, M., The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 373:6 (2006), 401–414, 10.1007/s00210-006-0082-1.
29. Guignabert, C., Raffestin, B., Benferhat, R., Raoul, W., Zadigue, P., Rideau, D., Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111:21 (2005), 2812–2819, 10.1161/CIRCULATIONAHA104524926.
30. Haberl, I., Frei, K., Ramsebner, R., Doberer, D., Petkov, V., Albinni, S., Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet 15:1 (2007), 18–22, 10.1038/sjejhg5201711.
31. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat Biotechnol 32:1 (2014), 40–51, 10.1038/nbt2786.
32. Heath, D., The rat is a poor animal model for the study of human pulmonary hypertension. Cardioscience 3:1 (1992), 1–6.
33. Hironaka, E., Hongo, M., Sakai, A., Mawatari, E., Terasawa, F., Okumura, N. Kinoshita, O., Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 60:3 (2003), 692–699.
34. Hoeper, M.M., Barst, R.J., Bourge, R.C., Feldman, J., Frost, A.E., Galié, N. Ghofrani, H.-A.A., Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 127:10 (2013), 1128–1138, 10.1161/CIRCULATIONAHA112000765.
35. Hsu, H.-H.H., Ko, W.-J.J., Hsu, J.-Y.Y., Chen, J.-S.S., Lee, Y.-C.C., Lai, I.-R.R., Chen, C.-F.F., Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Respir Res, 10, 2009, 32, 10.1186/1465-9921-10-32.
36. Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation, 2010, 10.1161/CIRCULATIONAHA109911818.
37. Ikeda, T., Nakamura, K., Akagi, S., Kusano, K.F., Matsubara, H., Fujio, H., Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 55:1 (2010), 39–48, 10.1097/FJC0b013e3181c0419c.
38. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, The interleukin-6 receptor as a target for prevention of coronary heart disease: A Mendelian randomisation analysis. Lancet (London, England) 379:9822 (2012), 1214–1224, 10.1016/S0140-6736(12)60110-X.
39. Ioannidis, J.P., Why most published research findings are false. PLoS Med, 2(8), 2005, e124, 10.1371/journalpmed0020124.
40. Izikki, M., Hanoun, N., Marcos, E., Savale, L., Barlier-Mur, A.M., Saurini, F., Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: Effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 293:4 (2007), L1045–L1052, 10.1152/ajplung000822007.
41. Kaitin, K.I., Deconstructing the drug development process: The new face of innovation. Clin Pharmacol Ther 87:3 (2010), 356–361, 10.1038/clpt2009293.
42. Kawut, S.M., Bagiella, E., Lederer, D.J., Shimbo, D., Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension ASA-STAT. Circulation, 2011, 10.1161/CIRCULATIONAHA110015693.
43. Keegan, A., Morecroft, I., Smillie, D., Hicks, M.N., MacLean, M.R., Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: Converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 89:12 (2001), 1231–1239.
44. Kieler, H., Artama, M., Engeland, A., Ericsson, O., Furu, K., Gissler, M., Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ (Clin Res Ed), 344, 2012, d8012.
45. Kola, I., Bell, J., A call to reform the taxonomy of human disease. Nat Rev Drug Discov 10:9 (2011), 641–642, 10.1038/nrd3534.
46. Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3:8 (2004), 711–715, 10.1038/nrd1470.
47. Kuang, T., Wang, J., Pang, B., Huang, X., Burg, E.D., Yuan, J.X., Wang, C., Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. Pulm Pharmacol Ther 23:5 (2010), 456–464, 10.1016/jpupt20100200.
48. Lane, K.B., Machado, R.D., Pauciulo, M.W., Thomson, J.R., Phillips, J.A., Loyd, J.E., Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26:1 (2000), 81–84, 10.1038/79226.
49. Lapka, R., Marek, J., Rejholec, V., Franc, Z., Pharmacokinetics of oral terguride in patients with a prolactinoma. Eur J Clin Pharmacol 30 (1986), 363–365, 10.1007/BF0054154.
50. Laudi, S., Trump, S., Schmitz, V., West, J., McMurtry, I.F., Mutlak, H., Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 293:3 (2007), L630–L638, 10.1152/ajplung001102006.
51. Launay, J.-M.M., Hervé, P., Callebert, J., Mallat, Z., Collet, C., Doly, S., Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood 119:7 (2012), 1772–1780, 10.1182/blood-2011-06-358374.
52. Launay, J.-M.M., Hervé, P., Peoc'h, K., Tournois, C., Callebert, J., Nebigil, C.G., Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:10 (2002), 1129–1135, 10.1038/nm764.
53. Lee, S.L., Wang, W.W., Lanzillo, J.J., Fanburg, B.L., Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Phys 266:1 Pt 1 (1994), L46–L52.
54. Leuchte, H.H., Baezner, C., Baumgartner, R.A., Bevec, D., Bacher, G., Neurohr, C., Behr, J., Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32:5 (2008), 1289–1294, 10.1183/0903193600050008.
55. Li, X.-L.L., Guan, R.-J.J., Li, J.-J.J., Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin. J Cardiovasc Pharmacol 60:2 (2012), 219–226, 10.1097/FJC0b013e31825cce63.
56. Li, X.-L.L., Guan, R.-J.J., Xu, Q.-H.H., Wu, Z.-Y.Y., Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats. Zhonghua Xin Xue Guan Bing Za Zhi 39:3 (2011), 247–253.
57. Li, M., Liu, Y., Dutt, P., Fanburg, B.L., Toksoz, D., Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol 293:2 (2007), L463–L471, 10.1152/ajplung001332007.
58. Liu, B., Wang, X.M., Zhou, T.F., Hua, Y.M., Liu, H.M., Wei, L., Expression of connective tissue growth factor and its down-regulation by simvastatin administration in pulmonary hypertensive rats. Zhonghua Er Ke Za Zhi 46:5 (2008), 359–365.
59. Machado, R.D., Koehler, R., Glissmeyer, E., Veal, C., Suntharalingam, J., Kim, M., Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 173:7 (2006), 793–797, 10.1164/rccm200509-1365OC.
60. Macintyre, P.D., Bhargava, B., Hogg, K.J., Gemmill, J.D., Hillis, W.S., The effect of iv sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 34:6 (1993), 541–546.
61. MacLean, M.R., Clayton, R.A., Templeton, A.G., Morecroft, I., Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 119:2 (1996), 277–282.
62. MacLean, M.R., Herve, P., Eddahibi, S., Adnot, S., 5-hydroxytryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131:2 (2000), 161–168, 10.1038/sjbjp0703570.
63. Macleod, M., Why animal research needs to improve. Nature, 477(7366), 2011, 511, 10.1038/477511a.
64. Marcos, E., Adnot, S., Pham, M.H., Nosjean, A., Raffestin, B., Hamon, M., Eddahibi, S., Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168:4 (2003), 487–493, 10.1164/rccm200210-1212OC.
65. McMurtry, M.S., Bonnet, S., Michelakis, E.D., Bonnet, S., Haromy, A., Archer, S.L., Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: The rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 293:4 (2007), L933–L940, 10.1152/ajplung003102006.
66. Millan, M.J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.-A.A., Newman-Tancredi, A., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor I A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:2 (2002), 791–804, 10.1124/jpet102039867.
67. Montani, D., Perros, F., Gambaryan, N., Girerd, B., Dorfmuller, P., Price, L.C., C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 184:1 (2011), 116–123, 10.1164/rccm201006-0905OC.
68. Morecroft, I., Dempsie, Y., Bader, M., Walther, D.J., Kotnik, K., Loughlin, L., Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49:1 (2007), 232–236, 10.1161/01HYP00002522105884978.
69. Morecroft, I., Heeley, R.P., Prentice, H.M., Kirk, A., MacLean, M.R., 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: Importance of the 5-HT1B receptor. Br J Pharmacol 128:3 (1999), 730–734, 10.1038/sjbjp0702841.
70. Morecroft, I., Loughlin, L., Nilsen, M., Colston, J., Dempsie, Y., Sheward, J., Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313:2 (2005), 539–548, 10.1124/jpet104081182.
71. Morecroft, I., Pang, L., Baranowska, M., Nilsen, M., Loughlin, L., Dempsie, Y., In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 85:3 (2010), 593–603 (Retrieved from https://cardiovascresoxfordjournalsorg/content/85/3/593full).
72. Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., Greyson, D., The cost of drug development: A systematic review. Health Policy (Amsterdam, Netherlands) 100:1 (2011), 4–17, 10.1016/jhealthpol201012002.
73. Mullard, A., Reliability of “new drug target” claims called into question. Nat Rev Drug Discov 10:9 (2011), 643–644, 10.1038/nrd3545.
74. Nishimura, T., Faul, J.L., Berry, G.J., Vaszar, L.T., Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166:10 (2002), 1403–1408.
75. Nishimura, T., Vaszar, L.T., Faul, J.L., Zhao, G., Berry, G.J., Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation, 2003, 10.1161/01CIR00000875924740137.
76. Oka, M., Fagan, K.A., Jones, P.L., McMurtry, I.F., Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 155:4 (2008), 444–454, 10.1038/bjp2008239.
77. Pei, Y., Ma, P., Wang, X., Zhang, W., Zhang, X., Zheng, P., Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 666:1–3 (2011), 165–172, 10.1016/jejphar201105035.
78. Perros, F., Montani, D., Dorfmüller, P., Durand-Gasselin, I., Tcherakian, C., Pavec, J.L., Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:1 (2008), 81–88, 10.1164/rccm200707-1037OC.
79. Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111:9 (2003), 1339–1346, 10.1172/JCI17500.
80. Porvasnik, S.L., Germain, S., Embury, J., Gannon, K.S., Jacques, V., Murray, J., PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther 334:2 (2010), 364–372, 10.1124/jpet109165001.
81. Prinz, F., Schlange, T., Asadullah, K., Believe it or not: How much can we rely on published data on potential drug targets?. Nat Rev Drug Discov, 10(9), 2011, 712, 10.1038/nrd3439-c1.
82. Rakotoniaina, Z., Guerard, P., Lirussi, F., Goirand, F., Rochette, L., Dumas, M., Bardou, M., The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: Comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 374:3 (2006), 195–206, 10.1007/s00210-006-0112-z.
83. Ridley, A.J., Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 16:10 (2006), 522–529, 10.1016/jtcb200608006.
84. Robinson, P.N., Köhler, S., Bauer, S., Seelow, D., Horn, D., Mundlos, S., The human phenotype ontology: A tool for annotating and analyzing human hereditary disease. Am J Hum Genet 83:5 (2008), 610–615, 10.1016/jajhg20080901.
85. Rothman, R.B., Ayestas, M.A., Dersch, C.M., Baumann, M.H., Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates Implications for primary pulmonary hypertension. Circulation 100:8 (1999), 869–875.
86. Ryan, J., Bloch, K., Archer, S.L., Rodent models of pulmonary hypertension: Harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl 172 (2011), 15–34, 10.1111/j1742-1241201102710x.
87. Saga, T., Said, S.I., Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 97 (1984), 304–310.
88. Said, S.I., Vasoactive intestinal peptide in pulmonary arterial hypertension. Am J Respir Crit Care Med, 185(7), 2012, 786, 10.1164/ajrccm1857786 (author reply 786).
89. Said, S.I., Hamidi, S.A., Dickman, K.G., Szema, A.M., Lyubsky, S., Lin, R.Z., Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115:10 (2007), 1260–1268, 10.1161/CIRCULATIONAHA106681718.
90. Satoh, M., Satoh, A., 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. J Pharm Pharm Sci 11 (2009), 118s–130s.
91. Satoh, K., Fukumoto, Y., Nakano, M., Sugimura, K., Nawata, J., Demachi, J., Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 81:1 (2009), 226–234, 10.1093/cvr/cvn244.
92. Schermuly, R.T., Dony, E., Ghofrani, H.A., Pullamsetti, S., Savai, R., Roth, M., Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:10 (2005), 2811–2821, 10.1172/JCI24838.
93. Simonneau, G., Fartoukh, M., Sitbon, O., Humbert, M., Jagot, J.L., Hervé, P., Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114:3 Suppl (1998), 195S–199S.
94. Smith, G.D., Ebrahim, S., Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 33:1 (2004), 30–42, 10.1093/ije/dyh132.
95. Stenmark, K.R., Meyrick, B., Galie, N., Mooi, W.J., McMurtry, I.F., Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:6 (2009), L1013–L1032, 10.1152/ajplung002172009.
96. Stroobants, S., Goeminne, J., Seegers, M., Dimitrijevic, S., Dupont, P., Nuyts, J., 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer (Oxford, England: 1990) 39:14 (2003), 2012–2020.
97. Sun, X., Ku, D.D., Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 294:2 (2008), H801–H809, 10.1152/ajpheart011122007.
98. Taraseviciene-Stewart, L., Scerbavicius, R., Choe, K.-H.H., Cool, C., Wood, K., Tuder, R.M., Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291:4 (2006), L668–L676, 10.1152/ajplung004912005.
99. Turner, S.J., Zhuang, S., Zhang, T., Boss, G.R., Pilz, R.B., Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol 75:2 (2008), 405–413, 10.1016/jbcp200708031.
100. Ullmer, C., Schmuck, K., Kalkman, H.O., Lübbert, H., Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett, 370, 1995, 10.1016/0014-5793(95)00828-W.
101. Wang, H.L., Dong, X., Zhang, X.H., Xing, J., 5-HT1B receptor augmented 5-HT vasoconstrictor response of pulmonary artery in monocrotaline-induced pulmonary hypertensive rats. Acta Pharmacol Sin 22:3 (2001), 269–273.
102. Welsh, D.J., Harnett, M., MacLean, M., Peacock, A.J., Proliferation and signaling in fibroblasts: Role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med 170:3 (2004), 252–259, 10.1164/rccm200302-264OC.
103. Wilkins, M.R., Ali, O., Bradlow, W., Wharton, J., Taegtmeyer, A., Rhodes, C.J., Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 181:10 (2010), 1106–1113, 10.1164/rccm200911-1699O.
104. Willers, E.D., Newman, J.H., Loyd, J.E., Robbins, I.M., Wheeler, L.A., Prince, M.A., Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173:7 (2006), 798–802, 10.1164/rccm200509-1361OC.
105. Wojciak-Stothard, B., Zhao, L., Oliver, E., Dubois, O., Wu, Y., Kardassis, D., Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res 110:11 (2012), 1423–1434, 10.1161/CIRCRESAHA112264473.
106. Wright, J.L., Zhou, S., Preobrazhenska, O., Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 183:1 (2011), 50–58, 10.1164/rccm201003-0399OC.
107. Xie, L., Lin, P., Xie, H., Xu, C., Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin Exp Hypertens 32:8 (2010), 547–554, 10.3109/106419632010503295.
108. Zeng, W.-J.J., Xiong, C.-M.M., Zhao, L., Shan, G.-L.L., Liu, Z.-H.H., Xue, F., Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J 40:1 (2012), 67–74, 10.1183/0903193600149011.
109. Zhang, W., Zhang, Y., Liu, C., Yu, B., Lu, W., Simvastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1–dependent pathway. Exp Lung Res, 2011, 10.3109/019021482011591892.
110. Zhang, W.-H.H., Lu, W.-X.X., Zhang, Y.-J.J., Ji, Y.-Q.Q., Liu, C.-P.P., Li, G., Simvastatin prevents the development of pulmonary hypertension in the rats through reduction of inflammation. Zhonghua Yi Xue Za Zhi 89:12 (2009), 855–859.
111. Zhang, Y., Zhang, J.-Q.Q., Liu, Z.-H.H., Xiong, C.-M.M., Ni, X.-H.H., Hui, R.-T.T. Pu, J.-L.L., VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population. Clin Genet 75:6 (2009), 544–549, 10.1111/j1399-0004200901196x.
112. Zhao, L., Sebkhi, A., Ali, O., Wojciak-Stothard, B., Mamanova, L., Yang, Q., Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 34:4 (2009), 948–957, 10.1183/0903193600143508.
113. Zhao, L., Zhou, T.F., Liu, H.M., Li, M., Dou, H., Tang, Z.H., Effect of simvastatin on rat pulmonary hypertension induced by high pulmonary blood flow and injected monocrotaline. Sichuan Da Xue Xue Bao Yi Xue Ban 38:3 (2007), 463–465 (479).
114. Zopf, D.A., Neves, L.A.A.d., Nikula, K.J., Huang, J., Senese, P.B., Gralinski, M.R., C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol 670:1 (2011), 195–203, 10.1016/jejphar201108015.